NCT01717391View on ClinicalTrials.gov

[F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 1, 2012

Primary Completion Date

February 29, 2016

Study Completion Date

April 30, 2017

Conditions
Uterine Cervical NeoplasmsEndometrial NeoplasmsAnus NeoplasmsRectal NeoplasmsProstatic Neoplasms
Interventions
DRUG

fluorothymidine F 18

A patient-specific bone marrow map will be designed from the pre-therapy FLT PET/CT imaging. A highly conformal radiation plan will be designed to spare active bone marrow.

Trial Locations (1)

52242

Holden Comprehensive Cancer Center, Iowa City

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Cancer Institute (NCI)

NIH

lead

John M. Buatti

OTHER

NCT01717391 - [F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers | Biotech Hunter | Biotech Hunter